Bursitis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(16 intermediate revisions by 4 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
Bursitis accounts for 400 visits per 100,000 visits to primary care clinic. The exact prevalence and incidence of bursitis is unknown.
Bursitis accounts for 400 visits per 100,000 visits to primary care clinics. The exact prevalence and incidence of bursitis are unknown.<ref name="pmid3074561">{{cite journal| author=McAfee JH, Smith DL| title=Olecranon and prepatellar bursitis. Diagnosis and treatment. | journal=West J Med | year= 1988 | volume= 149 | issue= 5 | pages= 607-10 | pmid=3074561 | doi= | pmc=1026560 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3074561  }} </ref>


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Prevalence and Incidence===
===Prevalence and Incidence===
*The exact incidence and prevalence of bursitis is not known.
*The exact incidence and prevalence of bursitis are not known.  
*The prevalence and incidence of bursitis may be influenced by the patient’s age gender and occupation.
*The incidence of septic [[olecranon]] and prepatellar bursitis is estimated to be 10 to 100 cases per 100,000 hospital admissions.<ref name="pmid3074561">{{cite journal| author=McAfee JH, Smith DL| title=Olecranon and prepatellar bursitis. Diagnosis and treatment. | journal=West J Med | year= 1988 | volume= 149 | issue= 5 | pages= 607-10 | pmid=3074561 | doi= | pmc=1026560 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3074561  }} </ref>
*The incidence of septic olecranon and prepatellar bursitis is estimated to be 10 to 100 cases per 100,000 hospital admissions.
*In sport medicine practice, the incidence of trochanteric bursitis was estimated to be 560 cases per 100,000 cases.<ref name="pmid17880718">{{cite journal| author=Brinks A, van Rijn RM, Bohnen AM, Slee GL, Verhaar JA, Koes BW et al.| title=Effect of corticosteroid injection for trochanter pain syndrome: design of a randomised clinical trial in general practice. | journal=BMC Musculoskelet Disord | year= 2007 | volume= 8 | issue=  | pages= 95 | pmid=17880718 | doi=10.1186/1471-2474-8-95 | pmc=2045096 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17880718  }} </ref>


===Age===
===Age===
*Prepatellar bursitis can affect all age groups. However, septic bursitis may occur in pediatrics age group (immunocompromised patients).
*Prepatellar bursitis can affect all age groups. However, the incidence of septic bursitis is higher in children, particularly immunocompromised patients.
*Olecranon bursitis affects middle-aged people (between the ages of 30 and 60 years).
*Olecranon bursitis affects middle-aged people (between the ages of 30 and 60 years).
*Trochanteric bursitis can affect all age groups, though the incidence of trochanteric bursitis may be higher in middle-aged to elderly adults.<ref name="pmid23766989">{{cite journal| author=Govaert LH, van Dijk CN, Zeegers AV, Albers GH| title=Endoscopic bursectomy and iliotibial tract release as a treatment for refractory greater trochanteric pain syndrome: a new endoscopic approach with early results. | journal=Arthrosc Tech | year= 2012 | volume= 1 | issue= 2 | pages= e161-4 | pmid=23766989 | doi=10.1016/j.eats.2012.06.001 | pmc=3678627 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23766989  }} </ref>
===Gender===
===Gender===
*Male are more commonly affected with prepatellar bursitis and septic bursitis than women.  
*Males are more commonly affected by prepatellar bursitis and septic bursitis than women.  
*Females are more commonly affected by [[trochanteric bursitis|trochanteric bursitis or greater trochanteric pain syndrome (GTPS)]] than male. The female to male ratio is approximately 4 to 1.<ref name="pmid23766989">{{cite journal| author=Govaert LH, van Dijk CN, Zeegers AV, Albers GH| title=Endoscopic bursectomy and iliotibial tract release as a treatment for refractory greater trochanteric pain syndrome: a new endoscopic approach with early results. | journal=Arthrosc Tech | year= 2012 | volume= 1 | issue= 2 | pages= e161-4 | pmid=23766989 | doi=10.1016/j.eats.2012.06.001 | pmc=3678627 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23766989  }} </ref>
 
===Race===
===Race===
*There is no racial predilection to the bursitis.
*There is no racial predilection to bursitis.
===Developed Countries===
 
===Developing Countries===


==References==
==References==
Line 27: Line 28:




{{WH}}
{{WS}}
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Rheumatology]]
[[Category:Orthopedics]]
[[Category:Orthopedics]]
[[Category:Rheumatology]]
[[Category:Surgery]]
[[Category:Primary care]]
[[Category:Emergency medicine]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
{{WH}}
{{WS}}

Latest revision as of 20:46, 29 July 2020

Bursitis Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Bursitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bursitis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bursitis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bursitis epidemiology and demographics

CDC on Bursitis epidemiology and demographics

Bursitis epidemiology and demographics in the news

Blogs on Bursitis epidemiology and demographics

Directions to Hospitals Treating Bursitis

Risk calculators and risk factors for Bursitis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]

Overview

Bursitis accounts for 400 visits per 100,000 visits to primary care clinics. The exact prevalence and incidence of bursitis are unknown.[1]

Epidemiology and Demographics

Prevalence and Incidence

  • The exact incidence and prevalence of bursitis are not known.
  • The incidence of septic olecranon and prepatellar bursitis is estimated to be 10 to 100 cases per 100,000 hospital admissions.[1]
  • In sport medicine practice, the incidence of trochanteric bursitis was estimated to be 560 cases per 100,000 cases.[2]

Age

  • Prepatellar bursitis can affect all age groups. However, the incidence of septic bursitis is higher in children, particularly immunocompromised patients.
  • Olecranon bursitis affects middle-aged people (between the ages of 30 and 60 years).
  • Trochanteric bursitis can affect all age groups, though the incidence of trochanteric bursitis may be higher in middle-aged to elderly adults.[3]

Gender

Race

  • There is no racial predilection to bursitis.

References

  1. 1.0 1.1 McAfee JH, Smith DL (1988). "Olecranon and prepatellar bursitis. Diagnosis and treatment". West J Med. 149 (5): 607–10. PMC 1026560. PMID 3074561.
  2. Brinks A, van Rijn RM, Bohnen AM, Slee GL, Verhaar JA, Koes BW; et al. (2007). "Effect of corticosteroid injection for trochanter pain syndrome: design of a randomised clinical trial in general practice". BMC Musculoskelet Disord. 8: 95. doi:10.1186/1471-2474-8-95. PMC 2045096. PMID 17880718.
  3. 3.0 3.1 Govaert LH, van Dijk CN, Zeegers AV, Albers GH (2012). "Endoscopic bursectomy and iliotibial tract release as a treatment for refractory greater trochanteric pain syndrome: a new endoscopic approach with early results". Arthrosc Tech. 1 (2): e161–4. doi:10.1016/j.eats.2012.06.001. PMC 3678627. PMID 23766989.


Template:WH Template:WS